WebMD

EGFR Exon 20 Insertion Mutation

When you’re diagnosed with lung cancer, your doctor will classify it as one of two types: small cell lung cancer or non-small-cell lung cancer (NSCLC). NSCLC is far more common. About 85% of all lung ...
Monthly Prescribing Reference

Rybrevant Combo Approved as First-Line Tx for NSCLC With EGFR Exon 20 Insertion Mutations

Results showed a statistically significant improvement in progression free survival in patients treated with amivantamab with carboplatin + pemetrexed compared with those who received carboplatin + ...
MedPage Today

Treatment Options for EGFR NSCLC With Mutations

In July 2025, the FDA greenlit the use of sunvozertinib (Zegfrovy) for pretreated locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 ...
Cure Today

Zegfrovy FDA Approved for EGFR Exon 20 Non-Small Cell Lung Cancer

Zegfrovy (sunvozertinib) received accelerated FDA approval for NSCLC patients with EGFR exon 20 insertion mutations post-platinum-based chemotherapy progression. The Oncomine Dx Express Test was ...

ArriVent BioPharma Reports First Quarter 2026 Financial Results

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ...
clinicaladvisor.com

FDA Greenlights Oral Therapy for NSCLC With EGFR Exon20 Insertion Mutations

In a primary efficacy population of 85 patients, the confirmed overall response rate was 46%. The Food and Drug Administration (FDA) has granted accelerated approval to Zegfrovy ® (sunvozertinib) for ...
Managed Healthcare Executive

FDA sets target date for zipalertinib for advanced lung cancer

The FDA has accepted a new drug application (NDA) for zipalertinib for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). If approved, it would be ...
MedPage Today

Exon 20 Insertion in NSCLC: How Do Patients Fare?

"For the majority of people with advanced EGFR-mutated NSCLC, we have highly effective targeted treatment options. However, for a minority with EGFR exon 20-mutated disease, these treatments don’t ...
Times Argus

U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 ...

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug ...
Seeking Alpha

ArriVent BioPharma: Bringing A Novel Cancer Drug From China

ArriVent BioPharma's lead molecule, firmonertinib, targets NSCLC with EGFR Exon 20 insertion mutations and shows potential in both classical and nonstandard EGFR mutations. Firmonertinib has ...

ArriVent BioPharma, Inc.: ArriVent BioPharma Reports First Quarter 2026 Financial Results

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent's dual-targeting MUC16/NaPi2b tetravalent AD ...